GLP-1 support, without the needle.
Sublingual troche
A semaglutide troche dissolves under the tongue — no injections involved. Systemic exposure is lower than with the weekly injection, and an independent licensed provider determines whether this route is appropriate for you.
Prescription required. Compounded medications are not approved or evaluated by the FDA for safety, effectiveness, or quality. A licensed provider will determine whether treatment is appropriate for you.
What is a semaglutide troche?
A troche is a small lozenge that dissolves under the tongue, where the medication absorbs through the tissue of the mouth rather than being injected. A semaglutide troche delivers the same class of GLP-1 medication by a different route, typically taken more frequently than a weekly injection.
The trade-off deserves honesty: less of the medication reaches the bloodstream sublingually than by injection, so systemic exposure is lower. Whether that fits your situation — or whether the more widely studied injectable route is the better recommendation — is a judgment the reviewing provider makes with your full health history in view. Individual results vary, and no outcome is guaranteed.
A compounded semaglutide troche is prepared by a state-licensed compounding pharmacy for an individual patient, pursuant to a licensed provider's prescription. It is not FDA-approved, and it is not the same as any FDA-approved oral semaglutide product.
How treatment works
Dissolves under the tongue
The troche is held under the tongue until it dissolves, and the medication absorbs across the mucosal tissue into circulation — no needles, no injection-day routine.
Same receptor pathway
Once absorbed, semaglutide acts on the same GLP-1 receptors as the injectable form — appetite signaling, gastric emptying, insulin response — at a lower level of systemic exposure.
Dosed by the provider
If prescribed, the reviewing provider sets the schedule and adjusts it based on how you respond — including recommending a different route if this one is not serving your treatment.
Troche and injection, compared
Sublingual troche
- Dissolves under the tongue — no needles involved
- Typically taken more frequently than weekly injections
- Lower systemic exposure than the injectable route
- An option a provider may consider where it fits
Injectable semaglutide
- Once-weekly subcutaneous dosing
- The more widely studied route
- Higher systemic exposure than the sublingual route
- May be the provider's recommendation where appropriate
Important safety information
Compounded medications are prepared by a state-licensed compounding pharmacy for an individual patient pursuant to a licensed provider's prescription. They are not FDA-approved, and the FDA does not review compounded medications for safety, effectiveness, or quality before they are dispensed. Compounded medications are not the same as, and are not generic versions of, any FDA-approved medication.
Who should not use a semaglutide troche
The route does not change the class contraindications: a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), pregnancy or breastfeeding, or a history of pancreatitis, severe gastrointestinal disease, or significant kidney disease. This list is not exhaustive — the reviewing provider makes the final decision.
Common side effects
Side effects are similar in kind to other forms of semaglutide — nausea, constipation, heartburn, and fatigue, most often around dose changes. A brief bitter taste while the troche dissolves is common. Lower systemic exposure does not make any side effect impossible, so report anything persistent to the prescribing provider.
A note on systemic exposure
Sublingual absorption delivers less medication to the bloodstream than injection. That is a fact about the route — not a promise about results, and not a claim that this form is safer. The reviewing provider will set honest expectations for what a troche can and cannot do.
Drug interactions
Share every medication and supplement you take during your consultation — prescription, over-the-counter, and herbal. Some combinations require closer screening, including medications that lower blood sugar. The reviewing provider evaluates your full profile before any prescription is written.
Pregnancy and breastfeeding
GLP-1 medications, in any form, are not recommended during pregnancy, while breastfeeding, or while actively trying to conceive. If your circumstances change during treatment, tell the prescribing provider promptly.
If a side effect appears
Contact the prescribing provider first — many effects settle with a schedule adjustment. For a severe allergic reaction, difficulty breathing, severe abdominal pain, or anything that feels like an emergency, call 911 or go to the nearest emergency room first.
Questions, answered.
No. A compounded semaglutide troche is not the same as, and is not a generic version of, any FDA-approved oral semaglutide product or any other FDA-approved medication.
It is prepared by a state-licensed compounding pharmacy for an individual patient pursuant to a provider's prescription, and it is not FDA-approved — the FDA does not review compounded medications for safety, effectiveness, or quality.
What can be stated plainly is mechanism: sublingual absorption produces lower systemic exposure than injection. What that means for you is a clinical question — no specific result can be promised with either route, and individual results vary. The reviewing provider will discuss which route, if any, is appropriate.
The prescribing provider sets the exact schedule. Sublingual semaglutide is typically taken more frequently than the weekly injection, and the provider will confirm the cadence that fits your prescription.
Route changes are a provider decision, made case by case. If the troche is not serving your treatment, or your preferences change, raise it with the prescribing provider — moving between forms is a conversation providers are used to having.
Yes. A compounded semaglutide troche is a prescription medication, available only if an independent licensed provider determines that a prescription is appropriate after a required medical consultation. It is never dispensed without one.
Eligibility is a medical decision made by an independent licensed provider — completing the assessment does not guarantee a prescription, and sometimes the honest answer is no. Services are not available in all states; see our States Served page for details.
A short set of questions about your goals, health background, and lifestyle, reviewed by an independent licensed provider who determines whether prescription treatment is appropriate — and in which form. Our How It Works page walks through the full process.
Start with the prescribing provider — many early side effects settle with a schedule adjustment. Our Safety page covers common side effects, the rare serious ones, and how to report a problem.
Other treatments a provider may consider
- Weekly subcutaneous injection
Compounded Semaglutide
A weekly GLP-1 injection that supports appetite regulation, available only when an independent licensed provider determines a prescription is appropriate.
- Weekly subcutaneous injection
Compounded Tirzepatide
A weekly injection that acts on both GIP and GLP-1 receptor pathways, considered case by case by the reviewing provider.
- Weekly injection
MIC+B12 Injections
A supportive blend of methionine, inositol, choline, and vitamin B12 that a provider may add alongside a broader weight-loss plan — not a weight-loss medication on its own.
Prescription required. Compounded medications are not approved or evaluated by the FDA for safety, effectiveness, or quality. A licensed provider will determine whether treatment is appropriate for you.
Explore the needle-free route.
A two-minute assessment is the first step. An independent licensed provider determines whether a troche — or another form of treatment — is appropriate for you.
Get StartedNo commitment required to complete the assessment.